Table 3 Observed infield acute and late severe (≥ grade 3) toxicity, graded by use of CTCAE v4.03
Patient (n) | Toxicity | Grade | Location SRT | Treated metastases (n) | Treatment dose (Gy/fx) | Concurrent therapy | Start of concurrent therapy | Systemic therapy paused during SRT |
|---|---|---|---|---|---|---|---|---|
Acute infield toxicity | ||||||||
1 | Headache | 3 | Brain | 3 | 24 Gy/1fx 100% Isodose) | Nivolumab | 8 days after SRT | – |
2 | Headache | 3 | Brain | 1 | 20 Gy/1fx (80% Isodose) | Bevacizumab | 365 days before SRT | No |
3 | Headache | 3 | Brain | 2 | 20 Gy/1fx (80% Isodose) | Nivolumab | 52 days before SRT | No |
Gait disturbance | 3 | |||||||
4 | Headache | 4 | Brain | 3 | 20 Gy/1fx (80% Isodose) | Nivolumab | 11 days after SRT | – |
Nausea | 3 | |||||||
5 | Dyspnea | 3 | Lung | 1 | 7 Gy/5fx (65% Isodose) | Gefitinib | 503 days before SRT | No |
6 | Thromboembolic event | 3 | Brain | 1 | 20 Gy/1fx (80% Isodose) | Osimertinib | 98 days before SRT | No |
Late infield toxicity | ||||||||
7 | Radionecrosis | 3 | Brain | 5 | 20 Gy/1fx (80% Isodose) | Afatinib | 22 days before SRT | No |
Nausea | 3 | |||||||
Hemiparesis | 4 | |||||||
8 | Weight loss | 3 | Lung | 1 | 7 Gy/5fx (65% Isodose) | Erlotinib | 575 days before SRT | 4 days |